Genetic Medicine
Calidi Biotherapeutics to Present RedTail Platform at H.C. Wainwright Global Investment Conference
Calidi Biotherapeutics will showcase its innovative RedTail platform at the H.C. Wainwright conference, highlighting its potential to revolutionize cancer treatment through systemic delivery of genetic medicines to metastatic sites.
Calidi Biotherapeutics Inc. Showcases Breakthrough in Cancer Treatment with Genetic Medicine Platform
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is pioneering a precision genetic medicine platform aimed at revolutionizing cancer treatment by targeting both primary and metastatic tumors with engineered viruses.
Calidi Biotherapeutics' Genetic Medicine Platform Featured in Editorial for Cancer Treatment Innovation
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been highlighted in an editorial for its precision genetic medicine platform, offering a novel approach to targeting cancer tumors amidst rising global diagnoses.
Calidi Biotherapeutics' Genetic Medicine Platform Highlighted for Potential Cancer Breakthrough
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been featured in an editorial for its precision genetic medicine platform, which could revolutionize cancer treatment by targeting tumors with engineered viruses.
Beam Therapeutics to Present Breakthrough Sickle Cell Disease Data at European Hematology Congress
Beam Therapeutics will reveal updated results from its BEACON trial on BEAM-101, an innovative ex vivo cell therapy targeting severe sickle cell disease, highlighting potential advances in genetic medicine treatment strategies.